Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Propeller Health

- PMLiVE

Novartis and Savient face NICE rejections

Jakavi and Krystexxa turned down for NHS use in England and Wales

Novartis building

Novartis’ omalizumab on track for filing in serious skin disease

Is active ingredient in asthma drug Xolair

- PMLiVE

How is pharma using Vine?

Companies begin experimenting with Twitter's six-second video app

- PMLiVE

Sandoz takes short route for biosimilar Enbrel approval

Novartis subsidiary initiates late-stage trial to support use in chronic plaque-type psoriasis

- PMLiVE

VIDEO: The effect of mobile health on patient adherence and outcomes

PMLiVE speaks to Geoff McCleary, VP / group director, mobile innovation, Digitas Health at ThinkDigital 2013

Novartis building

US FDA deems Novartis’ heart failure candidate a ‘breakthrough’

Serelaxin demonstrates ability to reduce shortness of breath and lower chance of dying

- PMLiVE

Novartis launches European advanced breast cancer campaign

Campaign launches with audio/visual installation

Novartis building

Jakavi shows long-term survival benefit in myelofibrosis

Trial demonstrates Novartis’ blood cancer drug cut risk of death by half over three years

Pharmacists take tablets to keep up in new NHS

Pharmacy group Alphega to offer free devices and tailored apps to its UK members

Mobile cancer game to accelerate search for a cure

Cancer Research UK will this year launch game that will harness 'citizen science'

- PMLiVE

Alcon wins initial NICE backing for Jetrea in rare eye condition

Would be first alternative to surgery available to vitreomacular traction patients in England and Wales

- PMLiVE

AstraZeneca boosts R&D prospects with Pearl acquisition

Deal to acquire respiratory firm could be worth up to $1.15bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links